GLOBAL DOT COM
GLOBAL DOT COM
Industry:
Graphic Design SEO Web Design
Founded:
2016-01-01
Address:
Hougang, North-East Region, Singapore
Country:
Singapore
Website Url:
http://www.globaldotcom.sg
Total Employee:
1+
Status:
Active
Contact:
65-6908-5866
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome
Similar Organizations
airplantz
airplantz is a creative graphic and website design agency.
Creative Canopy
Creative Canopy is a graphic and web design agency.
Creative Works
Creative Works is a creative strategy and design agency.
Just Design
Just Design is a graphic and web design agency.
Official Site Inspections
http://www.globaldotcom.sg Semrush global rank: 9.61 M Semrush visits lastest month: 132
- Host name: 91-109-115-211.as42831.net
- IP address: 91.109.115.211
- Location: Rugby United Kingdom
- Latitude: 52.3518
- Longitude: -1.2778
- Timezone: Europe/London
- Postal: CV22
More informations about "Global Dot Com"
FDA Approves Subcutaneous Administration of ENTYVIO® - Takeda
Sep 27, 2023 ENTYVIO is the only FDA-approved biologic for maintenance therapy in ulcerative colitis offering the option of either intravenous or subcutaneous administration.” The approval …See details»
Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based ...
Another study of open-label VDZ therapy, conducted by Narula et al, reported results from the multicenter hospital-based US VICTORY (Vedolizumab for Health Outcomes in Inflammatory …See details»
Infusions and Pen Injections | ENTYVIO® (vedolizumab)
One ENTYVIO. Two administration options. ENTYVIO is designed to fit your lifestyle, with two ways to administer maintenance therapy: intravenous (IV) infusion or self-administered …See details»
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO
Sep 27, 2023 U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative ColitisSee details»
ENTYVIO® (vedolizumab) Dosing and Administration
ENTYVIO® dosing and administration for IV infusion and subcutaneous injection. Find infusion schedule, storage, and injection site information.See details»
Centers for Medicare and Medicaid Services: Vedolizumab (Entyvio…
Comparators Data permitting, we intend to compare vedolizumab to drugs that are recommended by current guidelines and have Food and Drug Administration (FDA)-approved biosimilar …See details»
DRUG UANTITY ANAGEMENT POLICY ER AYS
Therapy begins with Entyvio 300 mg IV at Weeks 0, 2, and 6, followed by every 8 weeks thereafter.1Alternatively, at Week 6, or at any scheduled Entyvio IV infusion in patients with a …See details»
vedolizumab (Entyvio®) - Louisiana Blue
Aug 3, 2020 Based on review of available data, the Company may consider the use of vedolizumab (Entyvio®)‡ for the treatment of adult ulcerative colitis (UC) or adult Crohn’s …See details»
Subject: Vedolizumab (Entyvio®) Injection and Infusion
DESCRIPTION: Vedolizumab (Entyvio) intravenous (IV) infusion was approved by the US Food and Drug Administration (FDA) in May 2014 for the treatment of moderately to severely active …See details»
FDA approves subcutaneous administration of Entyvio (vedolizumab…
Apr 29, 2024 The subcutaneous administration of Entyvio was also approved by FDA in September 2023 for the maintenance treatment of adults with moderately to severely active …See details»